StockNews.AI
BHVN
StockNews.AI
15 days

Biohaven Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses.

1. Biohaven faces a class action lawsuit from investors over misstatements. 2. Investors claim company overstated prospects of BHV-7000 and troriluzole. 3. Stock saw significant declines due to failed drug trials and regulatory issues. 4. BHV-7000 failed to meet primary endpoints in clinical trials, impacting stock negatively. 5. Investors can claim losses until September 12, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The class action lawsuit over misrepresentations threatens investor confidence. Previous significant stock declines followed negative trial results.

How important is it?

Given the substantial allegations and investor actions, this news raises concerns about Biohaven's future, impacting stock performance.

Why Short Term?

Immediate effects from the lawsuit and clinical trial failures will likely impact stock soon. Historically, legal confrontations in biopharma result in swift market reactions.

Related Companies

VRTXNVS
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) investors of a class action representing investors that bought securities between March 24, 2023 and May 14, 2025, inclusive (the "Class Period"). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. CASE ALLEGATIONS: Biohaven is a biopharmaceutical company focused on discovering, developing, and commercializing therapies in the areas of immunology, neuroscience, and oncology. Among its key product candidates are troriluzole, being developed for the treatment of spinocerebellar ataxia (SCA), and BHV-7000, intended for the treatment of bipolar disorder and other indications. According to the class action lawsuit, Biohaven and its executives made false and/or misleading statements and/or failed to disclose material facts throughout the Class Period, specifically: That the regulatory prospects of troriluzole as a treatment for SCA — and the sufficiency of the data submitted in support of its New Drug Application (NDA) — were overstated;That the efficacy and clinical potential of BHV-7000 for treating bipolar disorder were similarly overstated; andThat disclosure of the true facts would have a materially negative impact on Biohaven’s business and financial outlook. The complaint cites several key disclosures that led to significant declines in Biohaven’s stock price: July 27, 2023: Biohaven announced that the U.S. Food and Drug Administration (FDA) had refused to review its NDA for troriluzole because the Phase 3 trial had failed to meet its primary endpoint. Following this news, Biohaven’s stock price fell by nearly 23%.March 3, 2025: Biohaven disclosed that recent late-stage clinical trial data for BHV-7000 in bipolar mania failed to statistically separate from the comparator on the primary outcome measure (the Young Mania Rating Scale). This announcement caused the stock to decline by nearly 14%.April 25, 2025: News reports emerged that Biohaven had withdrawn its Marketing Authorization Application for troriluzole in Europe in late March 2025, as confirmed by the European Medicines Agency. Following this development, Biohaven shares dropped by over 15%.May 14, 2025: Biohaven announced that the FDA’s Division of Neurology 1 had extended the Prescription Drug User Fee Act (PDUFA) date for the troriluzole NDA by three months to allow for a full review of recent submissions. The FDA also indicated plans to hold an advisory committee meeting, although no date had been scheduled. On this news, the company’s stock fell by more than 19%. The class action lawsuit alleges that investors suffered substantial losses due to the Company’s misrepresentations and omissions regarding the regulatory and clinical prospects of its key drug candidates. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News